Department of Brain Surgery, Ningbo Zhenhai People Hospital (Ningbo Seventh Hospital), Zhejiang 315202, China.
Diabetes Res Clin Pract. 2018 Apr;138:75-80. doi: 10.1016/j.diabres.2018.01.017. Epub 2018 Feb 3.
Although Hyperbaric oxygen therapy (HyperBOT) attract our attention successfully these days, it is still full of controversy on the treatment of acute stroke. The aim of this study is to assess the potential long-term neurological consequences and safety of using HyperBOT on intracerebral hemorrhage (ICH) in the diabetics.
In this prospective, randomized controlled trial, 79 diabetes patients suffering from acute ICH were randomized to treat for 60 min in a monoplace hyperbaric chamber pressurized with pure oxygen to 2.5-atm absolute (ATA) in the HyperBOT group or 1.5 ATA in the normobaric oxygen therapy (NormBOT) group, which was performed as control. Both short-term and long-term neurological consequences were studied and compared in each group on National Institutes of Health Stroke Scale [NIHSS], Barthel Index, modified Rankin Scale [mRS] and Glasgow Outcome Scale [GOS]. The related complications or side-events of all patients were recorded as well at the final follow-up of six months after onset.
No distinct difference was observed between each group at one month follow-up. However, in the long-term follow-up of six months, a higher frequency of patients in the HyperBOT group resulted into good outcome with a relative high neurological consequence compared with the NormBOT group (Barthel Index: 85.1% versus 65.6%, P = 0.080; mRS: 89.4% versus 68.8%, P = 0.045; GOS: 83.0% versus 62.5%, P = 0.073; NIHSS: 80.9% versus 56.2%, P = 0.035).
Early HyperBOT was found to be safe and effective with regards to the long-term neurological outcome of diabetic patients suffering from ICH.
尽管高压氧治疗（HyperBOT）近来备受关注，但在急性脑卒中的治疗方面仍存在诸多争议。本研究旨在评估糖尿病患者颅内出血（ICH）使用 HyperBOT 的潜在长期神经后果和安全性。
在这项前瞻性、随机对照试验中，79 名患有急性 ICH 的糖尿病患者被随机分为 HyperBOT 组和常压氧疗（NormBOT）组，每组 39 例。HyperBOT 组在单舱高压氧舱中用纯氧加压至 2.5 绝对大气压（ATA）治疗 60 分钟，NormBOT 组在 1.5ATA 下治疗，作为对照。分别在每个组中使用国立卫生研究院卒中量表（NIHSS）、巴氏指数、改良 Rankin 量表（mRS）和格拉斯哥结局量表（GOS）评估短期和长期神经后果。并在发病后 6 个月的最终随访时记录所有患者的相关并发症或不良事件。
在一个月的随访中，两组之间没有明显差异。然而，在 6 个月的长期随访中，HyperBOT 组有更多的患者神经后果较好，与 NormBOT 组相比结果更优（巴氏指数：85.1%比 65.6%，P=0.080；mRS：89.4%比 68.8%，P=0.045；GOS：83.0%比 62.5%，P=0.073；NIHSS：80.9%比 56.2%，P=0.035）。
早期 HyperBOT 被发现对糖尿病患者 ICH 的长期神经预后是安全有效的。
